A proposed framework to evaluate the quality and reliability of targeted metabolomics assays from the UK Consortium on Metabolic Phenotyping (MAP/UK)

Matthew R. Lewis, Sarir Sarmad, Mark R. Viant, Warwick B. Dunn, Royston Goodacre, Ian D. Wilson, Katie E. Chappell, Julian L. Griffin, Valerie B. O’Donnell, Brendon Naicker, Toru Suzuki

Published: 2023-02-23 DOI: 10.1038/s41596-022-00801-8

targeted metabolomics

reliability assessment

tiered approach

metabolic phenotyping

validation guidelines

AI 解读

Generation of mouse–human chimeric embryos

Genome-wide quantification of transcription factor binding at single-DNA-molecule resolution using methyl-transferase footprinting

Generation of CRISPR–Cas9-mediated genetic knockout human intestinal tissue–derived enteroid lines by lentivirus transduction and single-cell cloning

A puromycin-dependent activity-based sensing probe for histochemical staining of hydrogen peroxide in cells and animal tissues

Decoding personal biotic and abiotic airborne exposome

A clinically relevant model of focal embolic cerebral ischemia by thrombus and thrombolysis in rhesus monkeys

Bioengineering human intestinal mucosal grafts using patient-derived organoids, fibroblasts and scaffolds

Biomimetic tail-to-head terpene cyclizations using the resorcin[4]arene capsule catalyst

Neuroscience robotics for controlled induction and real-time assessment of hallucinations

Scanorama: integrating large and diverse single-cell transcriptomic datasets

Single-cell RNA sequencing (scRNA-seq)（单细胞RNA测序）

Data integration（数据集成）

Heterogeneity（异质性）

查看全部

Sections

Figures

References

Targeted metabolite assays that measure tens or hundreds of pre-selected metabolites, typically using liquid chromatography–mass spectrometry, are increasingly being developed and applied to metabolic phenotyping studies. These are used both as standalone
Discussion
Conclusions
References
ACKNOWLEDGMENTS

Kadian, N. et al. Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J. Pharm. Biomed. Anal. 126, 83–97 (2016).
Bliesner, D. M. Validating Chromatographic Methods: A Practical Guide (Wiley Interscience, 2006).
Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Targeted metabolomics. Curr. Protoc. Mol. Biol. 98, 30.2.1–30.2.24 (2012).
Goodacre, R., Vaidyanathan, S., Dunn, W. B., Harrigan, G. G. & Kell, D. B. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 22, 245–252 (2004).
Wei, R., Guodong, L. & Seymour, A. B. High-throughput and multiplexed LC/MS/MRM method for targeted metabolomics. Anal. Chem. 82, 5527–5533 (2010).
Dunn, W. B. et al. Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics 11, 9–26 (2015).
Guijas, C., Montenegro-Burke, J. R., Warth, B., Spilker, M. E. & Siuzdak, G. Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat. Biotechnol. 36, 316–320 (2018).
Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. Nat. Rev. Mol. Cell Biol. 20, 353–367 (2019).
Viant, M. R. et al. Use cases, best practice and reporting standards for metabolomics in regulatory toxicology. Nat. Commun. 10, 3041 (2019).
Gertsman, I. & Barshop, B. A. Promises and pitfalls of untargeted metabolomics. J. Inherit. Metab. Dis. 41, 355–366 (2018).
Rattray, N. J. W. et al. Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty. Nat. Commun. 10, 5027 (2019).
Ribbenstedt, A., Ziarrusta, H. & Benskin, J. P. Development, characterization and comparisons of targeted and non-targeted metabolomics methods. PLoS One 13, e0207082 (2018).
Want, E. J., Cravatt, B. F. & Siuzdak, G. The expanding role of mass spectrometry in metabolite profiling and characterization. Chem. BioChem. 6, 1941–1951 (2005).
Dunn, W. B. et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060–1083 (2011).
Goodman, J. et al. Update to the European Bioanalysis Forum recommendation on biomarkers assays; bringing context of use into practice. Bioanalysis 12, 1427–1437 (2020).
Tabassum, R. et al. Genetic architecture of human plasma lipidome and its link to cardiovascular disease. Nat. Commun. 10, 4329 (2019).
Goutman, S. A. et al. Untargeted metabolomics yields insight into ALS disease mechanisms. J. Neurol. Neurosurg. Psychiatry 91, 1329–1338 (2020).
Palmer, J. A. et al. A targeted metabolomics-based assay using human induced pluripotent stem cell-derived cardiomyocytes identifies structural and functional cardiotoxicity potential. Toxicol. Sci. 174, 218–240 (2020).
Michel, F., Pirotte, B., Fillet, M. & Tullio, P. Metabolomics as a challenging approach for medicinal chemistry and personalized medicine. J. Med. Chem. 59, 8649–8666 (2016).
Beger, R. D. et al. Metabolomics enables precision medicine: “A White Paper, Community Perspective. Metabolomics 12, 149 (2016).
Mandal, R., Chamot, D. & Wishart, D. S. The role of the human metabolome database in inborn errors of metabolism. J. Inherit. Metab. Dis. 41, 329–336 (2018).
Burla, B. et al. MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines. J. Lipid Res. 59, 2001–2017 (2018).
Thompson, J. W. et al. International ring trial of a high resolution targeted metabolomics and lipidomics platform for serum and plasma analysis. Anal. Chem. 91, 14407–14416 (2019).
König, R., Cave, A., Goldammer, M. & Meulendijks, D. Bioanalytical Omics Subgroup Report (Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA)); http://www.ema.europa.eu/en/documents/report/bioanalytical-omics-subgroup-report_en.pdf
Harrill, J. A. et al. Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology. Regul. Toxicol. Pharmacol. 125, 105020 (2021).
Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R. & Griffin, J. L. Systems level studies of mammalian metabolomes: the Roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 40, 387–426 (2011).
Dunn, W. B. et al. Quality assurance and quality control processes: summary of a metabolomics community questionnaire. Metabolomics 13, 50 (2017).
Broadhurst, D. et al. Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics 14, 72 (2018).
Hyötyläinen, T., Ahonen, L., Pöhö, P. & Orešič, M. Lipidomics in biomedical research-practical considerations. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1862, 800–803 (2017).
Beger, R. D. et al. Towards quality assurance and quality control in untargeted metabolomics studies. Metabolomics 15, 4 (2019).
Theodorsson, E. Validation and verification of measurement methods in clinical chemistry. Bioanalysis 4, 305–320 (2012).
Bioanalytical Method Validation, Guidance for Industry (US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM), 2018); http://www.fda.gov/media/70858/download
Guideline on Bioanalytical Method Validation (European Medicines Agency, 2011); http://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
ICH Guideline M10 on Bioanalytical Method Validation (European Medicines Agency, 2019); http://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf
Draft Guideline on Bioanalytical Method Validation in Pharmaceutical Development (Ministry of Health and Welfare, Japan, 2013); http://www.nihs.go.jp/drug/BMV/BMV_draft_130415_E.pdf
Good Manufacturing Practice for Drugs (2010 Revision) MOH Decree No. 79. (China Food and Drug Administration (CFDA), 2010); http://www.gmpsop.com/RegulatoryReference/CFDA/China_SFDA_Good_Manufacturing_Practice_for_Drugs.pdf
Finished Product (Medicine) Analytical Procedure Validations for Complementary Medicines, March 2006 (Austrailian Government, Therapeutic Goods Administration, 2006); http://www.tga.gov.au/sites/default/files/cm-analytical-procedure-finished.pdf
ANVISA Guide for Validation of Analytical and Bioanalytical Methods Resolution RE no.899 (Brazilian Sanitary Surveillance Agency, 2012).
Huynh-Ba, K. & Beumer Sassi, A. Anvisa: an introduction to a new regulatory agency with many challenges. AAPS Open 4, 9 (2018).
Essential Considerations for Successful Qualification of Novel Methodologies (EMA, 2017); http://www.ema.europa.eu/en/documents/other/essential-considerations-successful-qualification-novel-methodologies_en.pdf
Points to Consider Document: Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices (Critical Path Institute, 2019); http://c-path.org/wp-content/uploads/2019/06/evidconsid-whitepaper-analyticalsection2019.pdf
Viswanathan, C. T. et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24, 1962–1973 (2007).
Timmerman, P. et al. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum. Bioanalysis 2, 1185–1194 (2010).
Lowes, S. et al. Tiered approaches to chromatographic bioanalytical method performance evaluation: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J. 17, 17–23 (2015).
Nakamura, T. 7th Japan Bioanalysis Forum symposium: regulated bioanalysis, to a new stage. Bioanalysis 8, 2097–2102 (2016).
Booth, B. et al. Workshop report: Crystal City V—quantitative bioanalytical method validation and implementation: the 2013 Revised FDA Guidance. AAPS J. 17, 277–288 (2015).
Global Bioanalysis Consortium on Harmonisation of Bioanalytical Guidance (GBC, 2020); http://sites.google.com/site/globalbioanalysisconsortium/
Timmerman, P. et al. Tiered approach into practice: scientific validation for chromatography-based assays in early development—a recommendation from the European Bioanalysis Forum. Bioanalysis 7, 2387–2398 (2015).
Lavezzari, G. & Womack, A. W. Industry perspectives on biomarker qualification. Clin. Pharmacol. Ther. 99, 208–213 (2016).
Shah, V. P. et al. Bioanalytical method validation—a revisit with a decade of progress. Pharm. Res. 17, 1551–1557 (2004).
Safavi A. Exploratory Biomarker Testing—to Qualify or Validate the Assay? (BioAgilityx, 2021); http://www.bioagilytix.com/blog/2019/08/28/webinar-sneak-peek-exploratory-biomarker-testing-to-qualify-or-validate-the-assay/
Lewis, M. et al. An open platform for large scale LC-MS-based metabolomics. Preprint at ChemRxiv http://doi.org/10.26434/chemrxiv-2022-nq9k0 (2022).
Uwe, C. et al. Mass spectrometry-based multiplexing for the analysis of biomarkers in drug development and clinical diagnostics—how much is too much? Microchem. J. 105, 32–38 (2012).
Thway, T. M. et al. Assessment of incurred sample reanalysis for macromolecules to evaluate bioanalytical method robustness: effects from imprecision. AAPS J. 13, 291–298 (2011).
Van de Merbel, N. C. Quantitative determination of endogenous compounds in biological samples using chromatographic techniques. Trends Anal. Chem. 27, 924–933 (2008).
Thakare, R. et al. Quantitative analysis of endogenous compounds. J. Pharm. Biomed. Anal. 128, 426–437 (2016).
Tsikas, D. Bioanalytical method validation of endogenous substances according to guidelines by the FDA and other organizations: basic need to specify concentration ranges. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1093–1094, 80–81 (2018).
Wakamatsu, A. et al. Proposed selection strategy of surrogate matrix to quantify endogenous substances by Japan Bioanalysis Forum DG2015-15. Bioanalysis 10, 1349–1360 (2018).
ICH Guideline Q2(R2) on Validation of Analytical Procedures EMA/CHMP/ICH/82072/2006 (European Medicines Agency, 2022); http://www.ema.europa.eu/en/ich-q2-r1-validation-analytical-procedures-text-methodology
Analytical Method Validation (WHO, 2018); http://pharmaguidances.com/analytical-method-validation-as-per-who-technical-report-series-no-937/
Araujo, P. Key aspects of analytical method validation and linearity evaluation. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877, 2224–2234 (2009).
Boque, R. & Heyden, Y. V. The limit of detection. LC GC Eur. 22, 82–85 (2009).
Desimoni, E. & Brunetti, B. Signal to noise ratio; limit of detection; standard error of the regression; chromatographic/voltammetric/spectroscopic signals. Pharm. Anal. Acta. 6, 355 (2015).
U.S. Pharmacopeia. Document 1225, validation of compendial methods. Pharmacoepial Forum 31, 549 (2005).
Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry (Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2015); http://www.fda.gov/media/87801/download
Robouch, P., Stroka, J., Haedrich, J., Schaechtele, A., & Wenzl, T. Guidance Document on the Estimation of LOD and LOQ for Measurements in the Field of Contaminants in Feed and Food (European Commission, Centre Joint Research, 2016).
2002/657/EC: Commission Decision of 12 August 2002 Implementing Council Directive 96/23/EC Concerning the Performance of Analytical Methods and the Interpretation of Results (Text with EEA Relevance) (Notified under Document Number C (2002) 3044) (European Commission, 2002); http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2002:221:0008:0036:EN:PDF
Watson, D. G. Pharmaceutical Analysis 5th edn (Elsevier, 2020).
Lee, J. W. et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23, 312–328 (2006).
Simón-Manso, Y. et al. Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Anal. Chem. 85, 11725–11731 (2013).

A proposed framework to evaluate the quality and reliability of targeted metabolomics assays from the UK Consortium on Metabolic Phenotyping (MAP/UK)

Supplementary information

Supplementary Information

Supplementary Note

推荐阅读